MAPT and Alzheimer disease: Furthermore, other studies observed that ACEA (CB1 agonist) and WIN55,212-2 (CB1/CB2 agonist) decreased tau phosphorylation in mouse models of AD (Esposito et al. 2006; Aso et al. 2012).